ADVA-OPTICAL-NETWORKING
9.11.2021 09:02:10 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5400 TimeCard™ , enabling operators of data center network infrastructure and 5G open RAN architectures to achieve highly accurate and reliable distribution and synchronization of time. Built on the OSA 5400 SyncModule™ , ADVA’s new PCIe card brings sophisticated timing capabilities to any open compute server, transforming it into a precise and stable PTP grandmaster, boundary clock, slave clock or NTP server. The OSA 5400 TimeCard™ is the market’s first solution developed to the framework of the Open Compute Project’s (OCP) Time Appliance Project (TAP) and enhanced with both PTP and NTP functions. With advanced synchronization capabilities, it solves a key challenge for network operators as they virtualize their infrastructure and replace purpose-built hardware with standard servers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005255/en/
“Timing in data centers and other open compute cases like 5G open RAN is becoming increasingly crucial as a growing number of applications require new levels of performance. But the sub-microsecond synchronization needed for efficient resource sharing is something that open compute servers often cannot provide. Open compute customers need a way to inject the most advanced synchronization capabilities into their white box hardware. That’s why we’ve engineered our OSA 5400 TimeCard™. It brings our experience in network and application synchronization to open compute servers as well as open RAN equipment, enabling a whole new group of customers to benefit from our unique expertise,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our feature-rich OSA 5400 TimeCard™ meets and goes beyond OCP-TAP specifications. For data centers, finance and 5G infrastructure, it’s the key to bringing packet time distribution to the edge and access network.”
Developed specifically to OCP-TAP specifications, ADVA’s new OSA 5400 TimeCard™ is enhanced with an integrated GNSS receiver, PTP, NTP, PTP assurance, GNSS assurance and mitigation engines, as well as full sync management functionality. Easily plugged into a free PCIe slot of a standard open compute server or PC, it delivers extremely robust and precise synchronization. It offers a wide range of oscillator options to cost-effectively meet different levels of holdover requirements. Unlike competing solutions, the OSA 5400 TimeCard™ is designed for simplicity and assured operations. Its powerful control interface provides comprehensive device information as well as data on the performance of the timing network. The OSA 5400 TimeCard™ provides transparent assurance and can be managed by ADVA’s Ensemble Sync Director . Comprehensive visibility of the timing infrastructure puts operational teams in complete control, even with no specialist expertise in network synchronization.
“In a wide range of industries, the need is now being recognized for highly precise and stable synchronization of time and frequency across packet networks. But the race to roll our cost-effective standard hardware and embrace the advantages of server virtualization often leaves a timing gap. As strict synchronization is now vital for more and more applications, operators urgently need an efficient way to bring tight timing to open compute servers. Our OSA 5400 TimeCard™ is the answer,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Our PCIe pluggable card will empower data center operators, enterprises, utilities, broadcast networks, financial networks and 5G mobile service providers to harness time-sensitive applications through reliable, scalable and high-accuracy timing.”
Further details on the OSA 5400 TimeCard™ are available in these slides: https://adva.li/osa-5400-timecard-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005255/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom